No Data
BofA Securities Cuts Price Target on Recursion Pharmaceuticals to $10 From $12, Maintains Neutral Rating
Recursion Pharmaceuticals Announces 2 Key Investigational Oncology Drugs Advancing To Clinical Trials, Targeting High Unmet Needs In Hematologic Malignancies, Small-Cell Lung Cancer, & More
Express News | Recursion Pharmaceuticals Inc - First Patient to Be Dosed in Phase 1 Excelerize Trial in Q1 2025
Express News | Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & More
BofA Securities Maintains Recursion Pharmaceuticals(RXRX.US) With Hold Rating, Cuts Target Price to $10
Recursion to Present at 43rd Annual JP Morgan Healthcare Conference
比特币骗子勿扰 : NVDA just crashes during conferences.
Hatt bosdike OP 比特币骗子勿扰 : Well, that might be true idk. But my point here mainly $Recursion Pharmaceuticals (RXRX.US)$ $Nano X Imaging (NNOX.US)$
Hatt bosdike OP : And if u look at things. Mag 7 has grown too much in past 5-10 years. I m not betting my money on them but their eco system and the small companies they are investing in.
比特币骗子勿扰 Hatt bosdike OP : Pharmaceutical stocks are unpredictable, a failed clinical trial can cause a sharp drop. Don't expect ARK Invest to immediately boost it, it takes time. Countless ups and downs, who knows how many times. It's likely to continue rising once the company is close to profitability.
Hatt bosdike OP 比特币骗子勿扰 : I agree but it buy the rumour and sell the news kinda trade with rxrx nnox